Peramivir
- Generic Name
- Peramivir
- Brand Names
- Rapivab
- Drug Type
- Small Molecule
- Chemical Formula
- C15H28N4O4
- CAS Number
- 330600-85-6
- Unique Ingredient Identifier
- 9ZS94HQO3B
- Background
Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.
- Indication
Peramivir is indicated for the treatment of acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days.
- Associated Conditions
- Acute, uncomplicated Influenza
- Associated Therapies
- -
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
- Conditions
- InfluenzaInfluenza, Human
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 3000
- Registration Number
- NCT05648448
- Locations
- 🇧🇷
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦Laos-Oxford-Mahosot Wellcome Trust Research unit, Vientiane, Lao People's Democratic Republic
🇳🇵Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 16
- Registration Number
- NCT02665351
- Locations
- 🇨🇳
Prince of Wales Hospital, Hong Kong, Hong Kong, China
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT02635724
- Locations
- 🇺🇸
Peramivir Investigative Site, San Antonio, Texas, United States
🇺🇸Peramivir Investigational Site, Salt Lake City, Utah, United States
🇺🇸Peramivir investigative site, South Jordan, Utah, United States
ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 180
- Registration Number
- NCT02609399
- Locations
- 🇺🇸
Maricopa Integrated Health System, Phoenix, Arizona, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT02369159
- Locations
- 🇿🇦
Peramivir Investigative Site, Pretoria, South Africa
🇺🇸Peramivir investigative site, South Jordan, Utah, United States
A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT01224795
Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza
- Locations
- 🇺🇸
University of Massachusetts, Worcester, Massachusetts, United States
🇺🇸North Shore-Long Island Jewish Health System, Manhasset, New York, United States
🇺🇸The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
- Conditions
- MyalgiaFatigueSeasonal InfluenzaCoughNasal CongestionSore ThroatHeadache
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 234
- Registration Number
- NCT00957996
A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
- Conditions
- Acute, Uncomplicated Human Influenza
- Interventions
- Drug: PlaceboDrug: Peramivir
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 405
- Registration Number
- NCT00705406
- Locations
- 🇺🇸
Mercury Street Medical Group, PLLC, Butte, Montana, United States
🇺🇸West Houston Clinical Research, Houston, Texas, United States
🇦🇺Holdsworth House Medical Practice, Darlinghurst, Australia
Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 82
- Registration Number
- NCT00610935
- Locations
- 🇺🇸
Clopton Clinic, Jonesboro, Arkansas, United States
🇺🇸Kevin Adkins, MD, Mountain Home, Arkansas, United States
🇺🇸Integrated Medical Research PC, Ashland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.